Arch Therapeutics, Inc.
ARTHQ
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 148.20K | 130.60K | 115.40K | 75.80K | 37.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.20K | 130.60K | 115.40K | 75.80K | 37.90K |
| Cost of Revenue | 89.60K | 87.00K | 84.10K | 78.10K | 54.90K |
| Gross Profit | 58.60K | 43.60K | 31.20K | -2.50K | -17.30K |
| SG&A Expenses | 4.02M | 4.01M | 4.58M | 4.37M | 4.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.87M | 4.85M | 5.38M | 5.12M | 5.19M |
| Operating Income | -4.72M | -4.71M | -5.26M | -5.04M | -5.16M |
| Income Before Tax | -12.26M | -8.43M | -7.86M | -6.98M | -6.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.26 | -8.43 | -7.86 | -6.98 | -6.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.26M | -8.43M | -7.86M | -6.98M | -6.41M |
| EBIT | -4.72M | -4.71M | -5.26M | -5.04M | -5.16M |
| EBITDA | -4.72M | -4.71M | -5.26M | -5.04M | -5.15M |
| EPS Basic | -2.62 | -2.61 | -3.00 | -3.87 | -5.10 |
| Normalized Basic EPS | -1.54 | -1.63 | -1.87 | -2.42 | -3.18 |
| EPS Diluted | -2.62 | -2.61 | -3.00 | -3.87 | -5.10 |
| Normalized Diluted EPS | -1.54 | -1.63 | -1.87 | -2.42 | -3.18 |
| Average Basic Shares Outstanding | 22.15M | 18.99M | 15.75M | 12.29M | 5.04M |
| Average Diluted Shares Outstanding | 22.15M | 18.99M | 15.75M | 12.29M | 5.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |